Nivedita Hegdekar

About Nivedita Hegdekar

I help life sciences companies turn scientific complexity into commercial clarity.With a PhD in Biochemistry, a law degree in patent strategy, and 3+ years as a strategy consultant at IQVIA, I sit at the intersection of deep scientific expertise and business execution — a combination that\'s rare and increasingly essential in pharma and biotech. 🧬I\'ve led 18+ consulting engagements across immunology, oncology, rare disease, and GLP-1/obesity — spanning brand launch strategy, loss of exclusivity planning, cross-indication market assessments, and data-driven patient segmentation. I\'ve managed projects end-to-end, directed 100+ primary research interviews, and regularly present findings to senior commercial and medical leaders. What I bring to the table:🧪 Scientific credibility that earns trust with KOLs, MSLs, and R&D teams Commercial instincts honed across 10+ therapy areas and both emerging and established companies A track record of translating ambiguous market questions into strategies leadership actually acts onFeel free to reach out over LinkedIn or email at n••••••••@gmail.com

Experience

1. Strategy Consultant, Life Sciences

   IQVIA

   Feb 2023 — Present · Boston, MA, US

   Focus on patient engagement, and portfolio analysis for emerging and leading pharmaceutical companies. Successfully executed 18 projects, 6 of which I have served as a project manager HIGHLIGHTED PAST PROJECTS• Brand Launch Strategy – Assessed cross-market demand, competitive dynamics, and positioning considerations for a new molecule entering a crowded dermatology and rheumatology landscape, informing early launch and commercial strategy.• Cross-Indication Strategy & Market Insights – Led end-to-end market assessments across PSO, PSA, IBD, HS, and vitiligo, synthesizing epidemiology, treatment algorithms, and competitive intelligence to shape a multi-year strategy for an emerging immunology asset.• Loss of Exclusivity (LOE) – Conducted analogue analysis across 10 comparable products, identifying high-impact tactics to extend commercial value and defend share for a blockbuster oncology ADC approaching loss of exclusivity.• Obesity (GLP-1 Landscape) – Evaluated demand, patient segments, and prescriber behavior for multiple GLP-1 and obesity-focused entrants, informing commercial opportunity sizing and differentiation strategy.• Patient Engagement & Segmentation – Leveraged clinical, demographic, and consumer datasets to build seven data-driven patient segments, identify high-opportunity geographies, and optimize engagement approaches for two rare diseases and six additional conditions across immunology and oncology portfolios.• Primary Market Research Leadership – Directed primary research for nine major initiatives, including development of discussion guides and moderation of 100+ interviews with patients, physicians, office staff, specialty pharmacy executives, and payers to uncover actionable insights that shaped brand, access, and patient-support strategies.

Education

• International Institute of Information Technology Bangalore

  Post Graduate Diploma, Data Science

• University of Maryland Francis King Carey School of Law

  Master of Science in Law, Patent Law

• Institute Of Chemical Technology

  Bachelor's Degree, Pharmaceutical Sciences (B. Pharm)

• University of Mumbai

  Diploma, German Language and Literature

• University of Maryland, Baltimore (UMB)

  Doctor of Philosophy (PhD), Biochemistry and Molecular Biology